A European Project known as 3TR is looking for people in the U.S. and other countries with severe asthma to join its Patient Working Group. The 3TR Patient Workgroup will help researchers understand if a biological treatment is working or not for people with severe asthma.
Biological treatments are injected medications such as omalizumab [Xolair], mepolizumab [Nucala], reslizumab [Cinqair], benralizumab [Fasenra], dupilumab [Dupixent].
Currently, there is no agreement about what counts as ‘responding’ to biological treatment. For example, how much better should a patient feel? What improvement in their lung function is needed.
People with severe asthma will help researchers know what aspects of treatment they consider most important. This will help researchers understand if a biological treatment is working or not for people with severe asthma. In the future, doctors and patients will use this definition to decide whether a biological treatment should be continued or if alternative treatments should be used instead.
Who can take part?
We would like to invite you to take part if:
- You are 12 years of age or above and have severe asthma
- You are a parent or caregiver of a person with severe asthma who is 6 years of age or above
- You have taken or are currently taking biological therapy (not mandatory for participation)
- Able to read and communicate in English
- No specific skills are required
An introductory call with interested people will be organized. This call will provide more information about the project and activities. The Patient Working Group will meet by videoconference once a month for one hour.
What is the project?
This Patient Working Group is part of a European project called 3TR. This group is coordinated by European Lung Foundation and European Federation of Allergy and Airways Diseases Patients’ Associations.
The 3TR project aims to improve the care of patients with severe asthma. You can find out more about 3TR here: https://www.3tr-imi.eu/
Patients can express their interest to take part by August, 30, 2021. Send an email to Dr. Kate Khaleva, University of Southampton, at email@example.com.